TBO-309 is under clinical development by Heart Research Institute and currently in Phase II for Acute Ischemic Stroke. According to GlobalData, Phase II drugs for Acute Ischemic Stroke have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TBO-309’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TBO-309 overview
TBO-309 is under development for the treatment of acute ischemic stroke (AIS). It is administered through intravenous route and acts by targeting PI3K beta.
Heart Research Institute overview
Heart Research Institute is engaged in research and development of novel therapies, drugs and medical devices to treat cardiovascular diseases. The company is headquartered in Newtown, New South Wales, Australia.
For a complete picture of TBO-309’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.